PainResearch Phase

Neuropeptide FF

Overview

Neuropeptide FF (NPFF) is an octapeptide belonging to the RFamide family, characterized by an arginine-phenylalanine-amide motif at the C-terminus. It acts on two G protein-coupled receptors, NPFF1 and NPFF2, and modulates opioid-induced analgesia, tolerance, and hyperalgesia. NPFF is widely distributed in the central nervous system and participates in pain modulation, opioid tolerance mechanisms, and cardiovascular regulation. Its dual role as both a pronociceptive and anti-opioid peptide has generated interest in targeting its receptors for chronic pain management.

Key Research Findings

Preclinical rodent studies have demonstrated that NPFF receptor antagonists can prevent or reverse opioid tolerance and opioid-induced hyperalgesia. NPFF receptor agonists have shown potential in modulating morphine withdrawal symptoms in animal models. No human clinical trials targeting NPFF receptors have been reported to date, and therapeutic development remains at the discovery stage.

Route of Administration

Intracerebroventricular, Subcutaneous injection

Regulatory Status

Research Phase

Interested in Neuropeptide FF?

Find a verified provider experienced with Neuropeptide FF protocols in your area. All providers are credentialed and use compliant sourcing.

Find a Neuropeptide FF Provider

Related Peptides

Ziconotide (Prialt)

FDA Approved

A synthetic 25-amino acid peptide identical to omega-conotoxin MVIIA, a neurotoxin found in the venom of the marine cone snail Conus magus. Ziconotide selectively and reversibly blocks N-type voltage-gated calcium channels (Cav2.2) in the dorsal horn of the spinal cord, inhibiting neurotransmitter release from primary afferent nociceptive neurons. It provides analgesia without opioid receptor activation, tolerance development, or respiratory depression.

Difelikefalin (Korsuva)

FDA Approved

A selective kappa-opioid receptor (KOR) agonist peptide that does not cross the blood-brain barrier, providing peripheral analgesia and anti-pruritic effects without central opioid side effects such as euphoria, dysphoria, sedation, or addiction. Difelikefalin activates kappa receptors on peripheral sensory neurons and immune cells to reduce itch signaling and inflammation. Its restricted CNS penetration is a deliberate design feature to avoid abuse potential.

ARA-290

In Clinical Trials

A synthetic 11-amino acid peptide derived from the structure of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR), a heteromer of the EPO receptor and the beta common receptor (CD131). Unlike EPO, ARA-290 does not stimulate erythropoiesis or promote thrombosis. It produces cytoprotective, anti-inflammatory, and tissue-reparative effects by activating the IRR on neurons, immune cells, and endothelial cells.

Palmitoylethanolamide (PEA)

Research Phase

An endogenous fatty acid amide belonging to the N-acylethanolamine family, naturally produced by cells in response to tissue damage and inflammation. PEA acts primarily through peroxisome proliferator-activated receptor alpha (PPAR-alpha), downregulating mast cell activation and pro-inflammatory mediator release. It also modulates the endocannabinoid system via the entourage effect, enhancing anandamide activity at CB1/CB2 receptors and TRPV1 channels without directly binding cannabinoid receptors.